Beyond the presence of primarily resistant clones in sensitive EGFRm NSCLC cell populations as a key mechanism accounting for the emergence of acquired resistance to EGFR-TKIs, drug-tolerant persister cells (DTCs) surviving in the initial period of treatment represent another critical origin accounting for the emergence of acquired resistance (18, 19). This evidence concerns the gene EGFR and non-small cell lung carcinoma.